ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats |
| |
| Authors: | Carole Muller Kamal Yassin Luo-Sheng Li Magnus Palmblad Suad Efendic Per-Olof Berggren Anthony Cerami Michael Brines Claes-G?ran ?stenson |
| |
| Affiliation: | 1Dept of Molecular Medicine and Surgery, Karolinska Institutet (KI), Stockholm, Sweden;2The Rolf Luft Research Centre for Diabetes and Endocrinology, KI, Stockholm, Sweden;3Dept Vascular Surgery, Leiden University Medical Center, The Netherlands;4Araim Pharmaceuticals, Tarrytown, New York, United States of America |
| |
| Abstract: | Effects of ARA290 on glucose homeostasis were studied in type 2 diabetic Goto-Kakizaki (GK) rats. In GK rats receiving ARA290 daily for up to 4 wks, plasma glucose concentrations were lower after 3 and 4 wks, and hemoglobin A1c (Hb A1c) was reduced by ~20% without changes in whole body and hepatic insulin sensitivity. Glucose-stimulated insulin secretion was increased in islets from ARA290-treated rats. Additionally, in response to glucose, carbachol and KCl, islet cytoplasmic free Ca2+ concentrations, [Ca2+]i, were higher and the frequency of [Ca2+]i oscillations enhanced compared with placebo. ARA290 also improved stimulus–secretion coupling for glucose in GK rat islets, as shown by an improved glucose oxidation rate, ATP production and acutely enhanced glucose-stimulated insulin secretion. ARA290 also exerted an effect distal to the ATP-sensitive potassium (KATP) channel on the insulin exocytotic pathway, since the insulin response was improved following islet depolarization by KCl when KATP channels were kept open by diazoxide. Finally, inhibition of protein kinase A completely abolished effects of ARA290 on insulin secretion. In conclusion, ARA290 improved glucose tolerance without affecting hematocrit in diabetic GK rats. This effect appears to be due to improved β-cell glucose metabolism and [Ca2+]i handling, and thereby enhanced glucose-induced insulin release. |
| |
| Keywords: | |
|
|
